Holen Sie sich die Stockscreener-App
5.04
5.44%
0.26
Handel nachbörslich:
5.23
0.19
+3.77%
Schlusskurs vom Vortag:
$4.78
Offen:
$4.9
24-Stunden-Volumen:
155.61K
Relative Volume:
0.01
Marktkapitalisierung:
$9.13M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-37.75M
KGV:
-1.5508
EPS:
-3.25
Netto-Cashflow:
$-30.91M
1W Leistung:
+3.92%
1M Leistung:
+1,219%
6M Leistung:
+1,981%
1J Leistung:
+80.65%
1-Tages-Spanne:
$4.88
$5.30
1-Wochen-Bereich:
$4.74
$5.30
52-Wochen-Spanne:
$0.224
$10.19
Cellectar Biosciences Inc Stock (CLRB) Company Profile
Firmenname
Cellectar Biosciences Inc
Sektor
Branche
Telefon
(608) 441-8120
Adresse
100 CAMPUS DRIVE, FLORHAM PARK, NJ
Vergleichen Sie CLRB mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CLRB
Cellectar Biosciences Inc
|
5.04 | 13.43M | 0 | -37.75M | -30.91M | -3.25 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.55 | 119.76B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.93 | 59.14B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.81 | 41.40B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
577.92 | 32.96B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
279.16 | 26.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Cellectar Biosciences Inc Stock (CLRB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-05 | Fortgesetzt | Ladenburg Thalmann | Buy |
| 2020-07-01 | Eingeleitet | Oppenheimer | Outperform |
| 2020-01-21 | Fortgesetzt | ROTH Capital | Buy |
| 2019-09-13 | Eingeleitet | ROTH Capital | Buy |
| 2016-12-21 | Eingeleitet | Ladenburg Thalmann | Buy |
Cellectar Biosciences Inc Aktie (CLRB) Neueste Nachrichten
What makes Cellectar Biosciences Inc. stock price move sharplySafety First Trading Signals - Newser
All You Need to Know About Cellectar Biosciences (CLRB) Rating Upgrade to Buy - Yahoo Finance
Why Cellectar Biosciences Inc. stock attracts strong analyst attentionFree Stock Market Return Analysis - Newser
How Cellectar Biosciences Inc. stock performs during market volatilityGrowth Stock Monitor - Newser
Waldenstrom Macroglobulinemia Market Sees Surging Demand Across the 7MM Amid BTK Inhibitor Advancements | DelveInsight - GlobeNewswire Inc.
Sequoia Financial Advisors LLC Purchases 188,760 Shares of Cellectar Biosciences, Inc. (NASDAQ:CLRB) - Defense World
Cellectar Biosciences shares rise 3.59% premarket after closing $6.9 million public offering. - AInvest
Cellectar Biosciences Closes $6.9 Million Public Offering - MarketScreener
Cellectar Biosciences, Inc. Completes $6.9 Million Public Offering to Advance Cancer Treatment Development - Nasdaq
Cellectar Biosciences Announces Closing of $6.9 Million - GlobeNewswire
Cellectar Secures $6.9M Funding: Healthcare Funds Back New Breast Cancer Drug Development - Stock Titan
Cellectar Biosciences Announces Pricing of $6 Million Underwritten Public Offering | CLRB Stock News - GuruFocus
Cellectar Biosciences prices $6 million public offering - Investing.com
Cellectar Biosciences, Inc. Announces Pricing of Underwritten Public Offering for Approximately $6 Million - Quiver Quantitative
Cellectar Biosciences Announces Pricing of $6 Million Underwritten Public Offering - Yahoo Finance
Cellectar Biosciences (NASDAQ:CLRB) Rating Increased to Sell at Wall Street Zen - Defense World
Cellectar Biosciences, Inc. and Nusano Enter into Multi-Isotope Supply Agreement - MarketScreener
Cellectar Biosciences provides update on clinical programs and preclinical data - Investing.com
Cellectar and Nusano sign multi-year radioisotope supply agreement By Investing.com - Investing.com India
Breakthrough TNBC Treatment Advances: FDA to Review Novel Radiopharmaceutical Trial Protocol - Stock Titan
Cellectar Biosciences Announces One-for-Thirty Reverse Stock Split - The Manila Times
Cellectar Biosciences announces one-for-thirty reverse stock split - MarketScreener
Cellectar Biosciences (CLRB) Announces One-for-Thirty Reverse St - GuruFocus
Cellectar Biosciences announces 1:30 reverse stock split - Investing.com
Cellectar Biosciences (CLRB) Announces Reverse Stock Split | CLR - GuruFocus
Cellectar Biosciences Reports 1-for-30 Reverse Stock Split, Effective June 24 - marketscreener.com
Cellectar Biosciences Announces One-for-Thirty Reverse Stock Split | CLRB Stock News - GuruFocus
Cellectar Biosciences, Inc. Announces One-for-Thirty Reverse Stock Split Effective June 24, 2025 - Nasdaq
Roth Capital Issues Positive Estimate for CLRB Earnings - Defense World
Cellectar Biosciences Approves Reverse Stock Split Proposal - TipRanks
Cellectar Biosciences (CLRB) Reports Promising Phase 1 Trial Res - GuruFocus
Cellectar Biosciences Provides Update on CLOVER-2 Phase 1 - GlobeNewswire
Cellectar reports improved survival in pediatric brain tumor trial By Investing.com - Investing.com India
Cellectar reports improved survival in pediatric brain tumor trial - Investing.com
Cellectar Biosciences Provides Update on CLOVER-2 Phase 1 Clinical Trial of Iopofosine I 131 in Pediatric Patients with Relapsed/Refractory High-Grade Glioma - The Manila Times
Cellectar Biosciences Provides Update on CLOVER-2 Phase 1 Clinical Trial of Iopofosine I 131 in Pediatric Patients with Relapsed/Refractory High-Grade Glioma | CLRB Stock News - GuruFocus
Breakthrough: New Drug Doubles Survival Time in Aggressive Childhood Brain Cancer Trial - Stock Titan
Squarepoint Ops LLC Makes New Investment in Cellectar Biosciences, Inc. (NASDAQ:CLRB) - Defense World
Cellectar Biosciences announces $2.5 million stock sale By Investing.com - Investing.com India
Cellectar Biosciences Enters into Common Stock Agreements to Rai - GuruFocus
Cellectar Biosciences Expects to Raise $2.5 Million via Stock Sale, Warrant Exercise - marketscreener.com
Cellectar Biosciences (CLRB) Secures $2.5 Million from Stock Sal - GuruFocus
Are Medical Stocks Lagging Anixa Biosciences (ANIX) This Year? - Yahoo Finance
Cellectar Biosciences Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Material Modification to Rights of Security Holders, Regulation FD Disclosure, Financial Statements and Exhibits - Quantisnow
Cellectar Biosciences (CLRB) Secures $2.5M Through Stock Sale Agreements | CLRB Stock News - GuruFocus
Cellectar Biosciences announces $2.5 million stock sale - Investing.com Australia
Cellectar Biosciences Enters into Common Stock Agreements to Raise $2.5 Million Priced at Market Under Nasdaq Rules | CLRB Stock News - GuruFocus
Cellectar Biosciences Enters into Common Stock Agreements - GlobeNewswire
Cellectar Biosciences Enters into Common Stock Agreements to Raise $2.5 Million Priced at Market Under Nasdaq Rules - Yahoo Finance
FDA Designation Sparks Rally For This Biotech - The Globe and Mail
Cellectar Biosciences stock soars on FDA breakthrough designation - Investing.com Australia
Finanzdaten der Cellectar Biosciences Inc-Aktie (CLRB)
Umsatz
Nettogewinn
Free Cashflow
ENV
Cellectar Biosciences Inc-Aktie (CLRB) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Longcor Jarrod | Chief Operating Officer |
Jul 02 '25 |
Buy |
4.99 |
10,000 |
49,900 |
12,768 |
| Kolean Chad J | Chief Financial Officer |
Jul 02 '25 |
Buy |
4.99 |
5,000 |
24,950 |
6,418 |
| Longcor Jarrod | Chief Operating Officer |
Jan 10 '25 |
Buy |
0.28 |
30,000 |
8,400 |
83,141 |
3.40%
2.49%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):